TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: LASA · data 2026-11-02
Lasa Supergenerics Ltd.
In plain words
Price: 64.4% below its 52-week high of ₹12.48.
Delivery: 80.4% of traded shares were kept for delivery over the last 10 sessions, against 70.8% over the last 60.
Latest results: a net loss of ₹4 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹6 cr |
| Net profit (last 12 months) | ₹-17 cr |
| Sales growth, 3 years (yearly) | -42.1% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 53.6% (unchanged in a year), pledged 20.7%.
ROE -51.1%, ROCE -27.0%, operating margin -224.5%: how much profit it earns on the money it uses.
Debt/equity 0.20, Profit growth — and sales growth -42.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-51.1%).
- Thin operating margin (-224.5%).
- Promoters have pledged 20.7% of their shares.
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
LASA Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹1.23 crore, down 93.9% YoY and up 1,046.2% QoQ.
Net loss was ₹3.58 crore, a smaller loss than a year ago and a smaller loss than last quarter.
Operating margin was 113.4% (2.5% a year ago).
EPS was -₹0.71, less negative than a year ago and less negative than last quarter.
LASA के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1.23 करोड़; पिछले साल की तुलना में 93.9% की गिरावट, पिछली तिमाही की तुलना में 1,046.2% की बढ़त।
शुद्ध घाटा: ₹3.58 करोड़; एक साल पहले से घाटा कम हुआ, पिछली तिमाही से घाटा कम हुआ।
ऑपरेटिंग मार्जिन: 113.4% (एक साल पहले 2.5%)।
EPS: -₹0.71; एक साल पहले से कम ऋणात्मक, पिछली तिमाही से कम ऋणात्मक।
LASAના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1.23 કરોડ; ગયા વર્ષની સરખામણીએ 93.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 1,046.2% વધારો.
ચોખ્ખી ખોટ: ₹3.58 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ ઘટી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ ઘટી.
ઓપરેટિંગ માર્જિન: 113.4% (એક વર્ષ પહેલાં 2.5%).
EPS: -₹0.71; એક વર્ષ પહેલાંના કરતાં ઓછી નકારાત્મક, ગયા ક્વાર્ટરના કરતાં ઓછી નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-26
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 12 Sept 26Results Q1 FY27 results: loss narrowed vs a year ago -4.9% next session
- 29 May 26Results Q4 FY26 results: loss narrowed vs a year ago -5.3% next session
- 17 Apr 26Results Q3 FY26 results: turned to loss vs a year ago
- 14 Nov 25Results Q2 FY26 results: loss widened vs a year ago -2.8% next session
- 13 Aug 25Results Q1 FY26 results: loss widened vs a year ago
- 28 May 25Results Q4 FY25 results: loss narrowed vs a year ago
- 13 Feb 25Results Q3 FY25 results: turned to profit vs a year ago
- 15 Nov 24Results Q2 FY25 results: loss widened vs a year ago
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹1 cr | ₹-4 cr | — | -113.4% | -0.71 |
| Mar 2026 | ₹-0 cr | ₹-4 cr | — | 1963.0% | -0.83 |
| Dec 2025 | ₹2 cr | ₹-3 cr | -146.4% | -34.0% | -0.51 |
| Sept 2025 | ₹3 cr | ₹-6 cr | — | -130.6% | -1.25 |
Shareholding trend
| Holder | Sept 2026 | Mar 2026 | Dec 2025 | Sept 2025 |
|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% |
| Foreign institutions (FII) | 0.00% | — | — | — |
| Domestic institutions (DII) | — | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 31.71% | 31.71% | 31.83% | 32.21% |
| Number of shareholders | 27,702 | 27,702 | 28,120 | 28,656 |
Common questions
What was Lasa Supergenerics Ltd.'s latest quarterly profit?
Lasa Supergenerics Ltd. reported a net loss of ₹4 cr for the quarter ended Jun 2026, on revenue of ₹1 cr.
How much do promoters hold in Lasa Supergenerics Ltd.?
Promoters held 53.65% of Lasa Supergenerics Ltd. at the end of Sept 2026, with 20.66% of promoter shares pledged.
Is Lasa Supergenerics Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.2.
What is the 52-week high and low of Lasa Supergenerics Ltd.?
The 52-week high is ₹12.48 and the 52-week low is ₹4.44.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lasa Supergenerics Ltd. | ₹4.44 | ₹25 cr | — | — | -51.1% | -27% | 0.2 | -61.3% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹29.05 | ₹47 cr | 97.7 | — | 13.8% | 1.8% | 0.14 | -24.7% |
| Mangalam Drugs & Organics Ltd. | ₹29 | ₹46 cr | — | — | -35.2% | -22.8% | 1.08 | -56.0% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
| Medi-Caps Ltd. | ₹24.69 | ₹30 cr | — | — | -2.6% | -9.5% | 0 | -5.8% |
| Sunrest Lifescience Limited | ₹39.25 | ₹17 cr | 4.5 | 0.8 | 22.4% | 25.9% | 0.85 | -6.5% |
Compare LASA with BIOFILCHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LASA in TickerKhoj →